<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schatzberg, Alan F.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Agomelatine Demonstrates Broad Efficacy in Depression</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">Agomelatine, a melatonergic agonist and a selective 5-HT2c antagonist, is a novel antidepressant in development for major depressive disorder. This article discusses a meta-analysis of pooled data from three clinical studies. The objective of the meta-analysis was to determine whether gender or baseline severity of depression had any influence on agomelatine efficacy.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>